PCSK9 inhibition therapy through monoclonal antibodies or small interfering RNA (siRNA) leads to higher levels of hepatic LDLR, lower circulating LDL-C levels, and improved cardiovascular disorder outcomes and does not show any adverse side-effects [43–45]. The gene discussed is LDLR; the disease is cardiovascular disorder.